MTFB News and Press, Motif Bio plc From 02/14/19

Motif Bio (NASDAQ: MTFB ) -75%  on receiving CRL from FDA. More news on: Motif Bio, Inovio Pharmaceuticals, Inc., Sierra Wireless, Inc., Stocks on the move, Read more ...

NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration ...

Noteworthy events during the week of February 10 - 16 for healthcare investors. More news on: Momenta Pharmaceuticals, Inc., Motif Bio, AVEO Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...

NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Jefferies London Healthcare Conference Nove...

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at two upcoming scientific conferences. IDWeek 2018 October 3-7,...

SOMERVILLE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Di...

Iclaprim overview presented in State of the Art Lecture Safety analysis of diabetic patients in REVIVE ABSSSI trials shows fewer adverse events versus vancomycin Surveillance data confirm in vitro activity of iclaprim against wide variety of Gram-positive bacteria, including drug-resi...

NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data will be presented at the upcoming European Society of Clinical Microbiology and Infectiou...

Stocks in News: MTFB, MDXG FDA accepts Motif Bio's NDA with priority review for Iclaprim Discussion : FDA accepted for filing the NDA of Motif Bio’s ( MTFB ) iclaprim. Iclaprim is a gram-positive investigational antibiotic, targeted for the treatment of acute bacterial skin and...

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AVEO partner moves forward with a HER3 treatment in China Company: CANbridge Life Scien...